KOP Therapeutics
RESEARCH COLLABORATIONS

Built on Rigorous
Scientific Partnerships

KOP Therapeutics advances its knockdown oncology platform through collaborations with leading academic institutions, contract research organizations, and synthesis partners — ensuring every data point is independently validated.

RESEARCH NETWORK

Our Scientific Partners

BC Cancer Experimental Therapeutics

ACADEMIC RESEARCH PARTNER

BC Cancer Experimental Therapeutics

Preclinical research collaboration — experimental therapeutics program

Vancouver, British Columbia, Canada

Charles River Laboratories

CONTRACT RESEARCH ORGANIZATION

Charles River Laboratories

GLP-grade in vivo efficacy studies — PC3 xenograft model, biostatistician-confirmed results

Global CRO network

Thomas Jefferson University

ACADEMIC RESEARCH PARTNER

Thomas Jefferson University

Scientific advisory and research collaboration — Mathew Thakur, Professor of Radiology

Philadelphia, Pennsylvania, USA

GALENVS SCIENCESPREFERRED CRO

STRATEGIC CRO PARTNER

Galenvs Sciences

Active collaboration on next-generation TGM platform delivery optimization — 96-hr kill study (ED50/ED90), multivalent scaffold engineering, endosomal escape assays, and in vivo PK/PD studies targeting Q1 2027

Montreal, Quebec, Canada

BACHEM

PEPTIDE SYNTHESIS PARTNER

BACHEM

GMP-grade peptide synthesis for TGM platform constructs

Global

BioSynthesis

ASO SYNTHESIS PARTNER

BioSynthesis

Antisense oligonucleotide synthesis and quality control

Lewisville, Texas, USA

PRECLINICAL MODEL PARTNER

VoxCell

3D vascularized human tissue models for drug discovery — enabling physiologically relevant preclinical testing of KOP TGM platform constructs

Victoria, British Columbia, Canada

MISO Chip

PRECLINICAL MODEL PARTNER

MISO Chip

Patient-derived tumor-on-a-chip platform — ex vivo testing of anticancer agents on human tumors with native tumor microenvironment preserved, enabling human-relevant preclinical validation of KOP TGM constructs

Montreal, Quebec, Canada

PARTNERSHIP FRAMEWORK

How We Work With Partners

🔬

Research Partnerships

We collaborate with academic institutions and research hospitals to validate our platform in rigorous, independently-reviewed preclinical settings.

🏛️

CRO Relationships

Our CRO partners conduct GLP-grade studies that generate the biostatistician-confirmed data required for regulatory submissions and investor due diligence.

⚗️

Synthesis Partners

Peptide and ASO synthesis partners provide GMP-grade materials that meet the quality standards required for IND-enabling and clinical-stage development.

🤝

Strategic Partnerships

We are actively seeking pharmaceutical and biotech partners to co-develop pipeline programs, license platform technology, or provide development capital.

Interested in a Research or Commercial Partnership?

We welcome discussions with pharmaceutical companies, biotech firms, academic institutions, and investors.

CONTACT CORPORATE DEVELOPMENT VIEW PIPELINE
KOP Therapeutics

Advancing tumor-targeted RNA therapeutics toward IND-enabling development, partnership, and commercialization.

Preclinical Stage

DISCLAIMER

The information contained in this presentation is in summary form only, is not intended to be complete and may contain inadvertent or unintentional errors. No representation, warranty or guarantee, expressed or implied, is made as to the fairness, accuracy or completeness of information contained herein, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any security and is not intended to be relied upon as advice to investors or potential investors. KOP is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation.

This communication contains forward-looking statements, which relate to future events or future performance, that are neither promises nor guarantees and are subject to numerous risks and uncertainties that may cause future results to differ materially from those expected and does not constitute an offer to sell or a solicitation of an offer to buy any securities. KOP's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.

Also, this communication is intended for the sole use of the addressee(s) and may contain confidential, personal and/or privileged information. Unless you are the intended recipient, we ask that you do not retain, disclose, distribute, or take action relying on any information contained herein, and that you please alert us immediately of the erroneous delivery by return e-mail. Any communication received in error, or subsequent reply should be deleted or destroyed. Thank you for your cooperation.

COPYRIGHT AND TRADEMARK

The information in this presentation (including certain names, graphics, logos, icons, designs, words, titles or phrases) is protected by copyright and other laws and may not be copied, reproduced, modified, uploaded, posted, transmitted, or distributed in any way without KOP's prior written approval. Any unauthorized downloading, re-transmission, re-publication or other copying or modification of trademarks and/or the contents herein is strictly prohibited.

© 2026 KOP Therapeutics Inc. All rights reserved.

Montreal, Quebec, Canada · 604.256.9900